Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

8.9%

252 terminated/withdrawn out of 2822 trials

Success Rate

89.5%

+3.0% vs industry average

Late-Stage Pipeline

33%

938 trials in Phase 3/4

Results Transparency

72%

1545 of 2149 completed trials have results

Key Signals

185 recruiting1545 with results206 terminated46 withdrawn

Enrollment Performance

Analytics

Phase 1

940(35.0%)

Phase 2

723(26.9%)

Phase 3

659(24.5%)

Phase 4

279(10.4%)

N/A

81(3.0%)

Early Phase 1

7(0.3%)

2689Total

Phase 1(940)

Phase 2(723)

Phase 3(659)

Phase 4(279)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2822)

Showing 20 of 2822 trials

NCT06522386Phase 2Active Not Recruiting

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Role: collaborator

NCT07313813Phase 1Active Not Recruiting

A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

Role: lead

NCT07533019Phase 2Not Yet Recruiting

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Role: lead

NCT07299084Phase 1Recruiting

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

Role: lead

NCT07420283Phase 2Recruiting

A Study of Brenipatide in Participants With Opioid Use Disorder

Role: lead

NCT06993792Phase 3Recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Role: lead

NCT07533006Phase 2Not Yet Recruiting

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Role: lead

NCT03570749Phase 2Completed

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Role: lead

NCT03157128Phase 1Active Not Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Role: lead

NCT06972459Phase 3Recruiting

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Role: lead

NCT05487599Phase 1Recruiting

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Role: collaborator

NCT06458036Phase 2Recruiting

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Role: collaborator

NCT02688712Phase 2Active Not Recruiting

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Role: collaborator

NCT06238479Phase 1Active Not Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Role: lead

NCT05509790Phase 1Active Not Recruiting

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Role: lead

NCT05929079Phase 3Active Not Recruiting

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Role: lead

NCT04623541Phase 1Active Not Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Role: collaborator

NCT06662383Phase 3Active Not Recruiting

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Role: lead

NCT06810544Phase 1Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Role: collaborator

NCT05113537Phase 1Recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Role: collaborator